Viemed Healthcare: Remaining Bullish Due To Strong Forward-Looking EPS Revisions
Viemed Healthcare's stock has declined recently, but bullish EPS revisions and strong growth projections make it an attractive buy near its long-term bottom. The company projects significant revenue and EBITDA growth for 2025, with EPS expected to rise by 42.86% in 2025 and 52.5% in 2026. Viemed's valuation remains attractive, with positive cash flow and rising equity, despite the stock's recent bearish trend.
Viemed Healthcare, Inc. (VMD) Q4 2024 Earnings Call Transcript
Viemed Healthcare, Inc. (NASDAQ:VMD ) Q4 2024 Earnings Conference Call March 11, 2025 11:00 AM ET Company Participants Todd Zehnder - COO Trae Fitzgerald - CFO Casey Hoyt - CEO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Andrew Rem - Odinson Partners Operator Greetings, and welcome to the Viemed Healthcare Year-End 2024 Earnings Call. At this time all participants are in a listen-only mode.
Viemed Healthcare, Inc. (VMD) Q3 2024 Earnings Call Transcript
Viemed Healthcare, Inc. (NASDAQ:VMD ) Q3 2024 Results Conference Call November 7, 2024 12:00 PM ET Company Participants Todd Zehnder - Chief Operating Officer Casey Hoyt - Chief Executive Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Doug Cooper - Beacon Securities Ilya Zubkov - Freedom Broker Operator Greetings, and welcome to Viemed's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Viemed Healthcare: Turning Bullish Once More On Growing Ventilator Patient Numbers
Upgraded Viemed Healthcare to 'Buy' due to bullish technicals, strong Q2 earnings, and promising growth trends in ventilator and sleep businesses. Bullish MACD crossover and strong buying volume signal potential for sustained share price increase. Q2 revenue hit $55 million, with notable organic growth and successful sales force restructuring driving performance.
